Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Payables (2019 - 2025)

Historic Payables for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $6.5 million.

  • Pulmonx's Payables rose 3957.22% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 3957.22%. This contributed to the annual value of $7.0 million for FY2024, which is 9175.79% up from last year.
  • According to the latest figures from Q3 2025, Pulmonx's Payables is $6.5 million, which was up 3957.22% from $6.7 million recorded in Q2 2025.
  • Over the past 5 years, Pulmonx's Payables peaked at $18.9 million during Q4 2021, and registered a low of $1.8 million during Q4 2022.
  • Its 5-year average for Payables is $8.0 million, with a median of $6.5 million in 2025.
  • As far as peak fluctuations go, Pulmonx's Payables crashed by 9022.53% in 2022, and later soared by 18030.86% in 2024.
  • Quarter analysis of 5 years shows Pulmonx's Payables stood at $18.9 million in 2021, then tumbled by 90.23% to $1.8 million in 2022, then soared by 97.62% to $3.7 million in 2023, then soared by 91.76% to $7.0 million in 2024, then dropped by 6.83% to $6.5 million in 2025.
  • Its Payables stands at $6.5 million for Q3 2025, versus $6.7 million for Q2 2025 and $12.1 million for Q1 2025.